UNSPSC 51112611: Ranimustine

This classification denotes a nitrosourea compound with the molecular formula C10H18ClN3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RYH2T97J77, chemically known as glucopyranoside, methyl-6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-, alpha-d- but more generally known as ranimustine, which bears US NIH Compound Identifier 71741. European Medicines Agency schedules Ranimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10256MIG.

UNSPSC 51112611 Ranimustine is a Commodity code for a specific pharmaceutical active ingredient used in cancer treatment. State and local governments procure ranimustine primarily through health and human services departments managing pharmacy benefit programs for state employees, retirees, and Medicaid beneficiaries. The work involves sourcing, contracting, and fulfillment of this controlled pharmaceutical product, often through direct-to-manufacturer relationships, pharmacy benefit managers, group purchasing organizations, or wholesale distributors. Issuing bodies are typically state health and human services commissions responsible for pharmacy benefit administration and cost management across large covered populations.

The Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities regarding direct-to-manufacturer prescription programs. The RFI sought information from vendors and stakeholders about establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management, including vendor experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on negotiated net pricing models, and capability to implement value-based or outcomes-based agreements. This exploratory procurement mechanism indicates the state is gathering market intelligence to inform future formal solicitations before developing detailed procurement specifications and implementation timelines. No award value or specific funding allocation was identified in the RFI materials at that preliminary stage.